 Jeffrey Maki
Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Magnetic Resonance Angiography | 35 | 2021 | 210 | 8.300 |
Why?
| | Contrast Media | 40 | 2021 | 373 | 7.240 |
Why?
| | Gadolinium | 20 | 2021 | 79 | 4.220 |
Why?
| | Image Enhancement | 22 | 2019 | 181 | 4.130 |
Why?
| | Image Interpretation, Computer-Assisted | 10 | 2017 | 220 | 3.030 |
Why?
| | Organometallic Compounds | 12 | 2019 | 88 | 2.890 |
Why?
| | Magnetic Resonance Imaging | 30 | 2023 | 3174 | 2.720 |
Why?
| | Meglumine | 9 | 2019 | 12 | 2.330 |
Why?
| | Renal Artery Obstruction | 10 | 2009 | 32 | 1.890 |
Why?
| | Lymphedema | 3 | 2017 | 21 | 1.670 |
Why?
| | Lymphography | 4 | 2020 | 6 | 1.570 |
Why?
| | Gadolinium DTPA | 9 | 2015 | 54 | 1.380 |
Why?
| | Sensitivity and Specificity | 19 | 2021 | 1795 | 1.320 |
Why?
| | Ferrosoferric Oxide | 3 | 2017 | 26 | 1.260 |
Why?
| | Arteries | 3 | 2016 | 250 | 1.250 |
Why?
| | Liver Neoplasms | 5 | 2015 | 527 | 1.230 |
Why?
| | Algorithms | 10 | 2018 | 1541 | 1.210 |
Why?
| | Liver Cirrhosis | 3 | 2014 | 245 | 1.210 |
Why?
| | Models, Cardiovascular | 4 | 2016 | 180 | 1.160 |
Why?
| | Imaging, Three-Dimensional | 9 | 2017 | 499 | 1.150 |
Why?
| | Pulmonary Embolism | 2 | 2019 | 183 | 1.140 |
Why?
| | Renal Artery | 7 | 2021 | 30 | 1.070 |
Why?
| | Blood Chemical Analysis | 2 | 2016 | 95 | 1.000 |
Why?
| | Liver | 5 | 2023 | 1816 | 0.990 |
Why?
| | Peripheral Vascular Diseases | 4 | 2009 | 98 | 0.960 |
Why?
| | Peliosis Hepatis | 1 | 2023 | 2 | 0.920 |
Why?
| | Magnetic Resonance Imaging, Cine | 4 | 2014 | 154 | 0.900 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2015 | 227 | 0.890 |
Why?
| | Lymphatic Vessels | 2 | 2020 | 54 | 0.850 |
Why?
| | Water | 3 | 2016 | 425 | 0.850 |
Why?
| | Image Processing, Computer-Assisted | 10 | 2014 | 709 | 0.800 |
Why?
| | Reproducibility of Results | 18 | 2019 | 2874 | 0.780 |
Why?
| | Artifacts | 11 | 2019 | 125 | 0.710 |
Why?
| | Patient-Specific Modeling | 2 | 2016 | 37 | 0.670 |
Why?
| | Blood Flow Velocity | 3 | 2016 | 327 | 0.670 |
Why?
| | Venous Thrombosis | 1 | 2019 | 147 | 0.590 |
Why?
| | Middle Aged | 29 | 2019 | 27617 | 0.540 |
Why?
| | Humans | 65 | 2023 | 118974 | 0.530 |
Why?
| | Blood Vessels | 2 | 2016 | 187 | 0.530 |
Why?
| | Computer Simulation | 8 | 2017 | 922 | 0.510 |
Why?
| | Magnetics | 2 | 2016 | 38 | 0.490 |
Why?
| | Lymph Node Excision | 1 | 2015 | 158 | 0.480 |
Why?
| | Radiology Information Systems | 1 | 2014 | 31 | 0.480 |
Why?
| | Medical Records Systems, Computerized | 1 | 2014 | 92 | 0.470 |
Why?
| | User-Computer Interface | 1 | 2014 | 163 | 0.450 |
Why?
| | Phantoms, Imaging | 6 | 2018 | 139 | 0.440 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2013 | 90 | 0.440 |
Why?
| | Lymph Nodes | 1 | 2015 | 455 | 0.430 |
Why?
| | Documentation | 1 | 2014 | 175 | 0.420 |
Why?
| | Elasticity Imaging Techniques | 1 | 2012 | 44 | 0.410 |
Why?
| | Hemangiosarcoma | 1 | 2012 | 19 | 0.410 |
Why?
| | Blood Proteins | 1 | 2013 | 248 | 0.410 |
Why?
| | Oxygen | 1 | 2016 | 854 | 0.410 |
Why?
| | Aneurysm, False | 1 | 2012 | 46 | 0.400 |
Why?
| | Heart Neoplasms | 1 | 2012 | 50 | 0.400 |
Why?
| | Osteitis Deformans | 1 | 2010 | 5 | 0.380 |
Why?
| | Coronary Sinus | 1 | 2010 | 7 | 0.380 |
Why?
| | Male | 32 | 2019 | 57801 | 0.370 |
Why?
| | Heart | 1 | 2014 | 631 | 0.370 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2010 | 12 | 0.370 |
Why?
| | Cell Membrane | 1 | 2013 | 710 | 0.360 |
Why?
| | Heart Septal Defects, Atrial | 1 | 2010 | 50 | 0.360 |
Why?
| | Coronary Vessels | 1 | 2012 | 233 | 0.360 |
Why?
| | Software | 1 | 2014 | 613 | 0.350 |
Why?
| | Skull | 1 | 2010 | 127 | 0.350 |
Why?
| | Transducers | 1 | 2009 | 27 | 0.340 |
Why?
| | Restraint, Physical | 1 | 2009 | 94 | 0.340 |
Why?
| | Abdomen | 3 | 1998 | 110 | 0.340 |
Why?
| | Aged | 19 | 2017 | 19657 | 0.320 |
Why?
| | Adult | 20 | 2019 | 31512 | 0.320 |
Why?
| | Female | 30 | 2019 | 61565 | 0.310 |
Why?
| | Microcirculation | 4 | 1991 | 155 | 0.310 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 248 | 0.300 |
Why?
| | Hematocrit | 1 | 2006 | 91 | 0.290 |
Why?
| | Veins | 1 | 2006 | 60 | 0.290 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2016 | 1945 | 0.280 |
Why?
| | Heterocyclic Compounds | 2 | 2016 | 21 | 0.280 |
Why?
| | Respiration | 3 | 2007 | 183 | 0.260 |
Why?
| | Radiology | 1 | 2007 | 199 | 0.240 |
Why?
| | Nephrogenic Fibrosing Dermopathy | 2 | 2015 | 8 | 0.230 |
Why?
| | Prospective Studies | 7 | 2019 | 6471 | 0.220 |
Why?
| | Tomography, X-Ray Computed | 5 | 2018 | 2436 | 0.220 |
Why?
| | Injections, Intravenous | 3 | 2019 | 210 | 0.220 |
Why?
| | Carotid Arteries | 2 | 2007 | 184 | 0.210 |
Why?
| | Constriction, Pathologic | 2 | 2021 | 203 | 0.210 |
Why?
| | Observer Variation | 4 | 2018 | 309 | 0.210 |
Why?
| | Thorax | 2 | 2019 | 45 | 0.210 |
Why?
| | ROC Curve | 3 | 2014 | 473 | 0.210 |
Why?
| | Feasibility Studies | 3 | 2019 | 749 | 0.200 |
Why?
| | Angiography, Digital Subtraction | 4 | 2021 | 46 | 0.200 |
Why?
| | Lymphatic System | 1 | 2020 | 13 | 0.190 |
Why?
| | Benchmarking | 1 | 2021 | 172 | 0.180 |
Why?
| | Phlebography | 2 | 2019 | 40 | 0.180 |
Why?
| | Motion | 3 | 2009 | 95 | 0.180 |
Why?
| | Monte Carlo Method | 2 | 2017 | 146 | 0.180 |
Why?
| | Radiation Exposure | 1 | 2019 | 44 | 0.160 |
Why?
| | Computed Tomography Angiography | 1 | 2019 | 81 | 0.160 |
Why?
| | Pelvis | 1 | 2019 | 92 | 0.160 |
Why?
| | Cardiac Imaging Techniques | 1 | 2017 | 13 | 0.160 |
Why?
| | Models, Statistical | 2 | 2015 | 636 | 0.160 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2018 | 109 | 0.150 |
Why?
| | Aged, 80 and over | 6 | 2008 | 6561 | 0.150 |
Why?
| | Radiation Dosage | 2 | 2018 | 147 | 0.150 |
Why?
| | Total Quality Management | 1 | 2017 | 61 | 0.150 |
Why?
| | Computer-Aided Design | 1 | 2016 | 42 | 0.140 |
Why?
| | Injections, Intra-Arterial | 1 | 2016 | 25 | 0.140 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1440 | 0.140 |
Why?
| | Surface-Active Agents | 1 | 2017 | 81 | 0.140 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 63 | 0.140 |
Why?
| | Arteriovenous Malformations | 1 | 2016 | 24 | 0.140 |
Why?
| | Predictive Value of Tests | 3 | 2010 | 1868 | 0.130 |
Why?
| | Prenatal Diagnosis | 1 | 2017 | 168 | 0.130 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 298 | 0.130 |
Why?
| | Sarcoidosis | 1 | 2017 | 130 | 0.130 |
Why?
| | Diffusion | 4 | 1991 | 122 | 0.130 |
Why?
| | Blood | 1 | 2015 | 100 | 0.130 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 536 | 0.130 |
Why?
| | Single-Blind Method | 1 | 2015 | 269 | 0.120 |
Why?
| | Aorta | 1 | 1997 | 367 | 0.120 |
Why?
| | Software Validation | 1 | 2014 | 7 | 0.120 |
Why?
| | Microcomputers | 1 | 2014 | 13 | 0.120 |
Why?
| | Software Design | 1 | 2014 | 23 | 0.120 |
Why?
| | Plasma | 1 | 2016 | 224 | 0.120 |
Why?
| | Surgery, Computer-Assisted | 1 | 2015 | 69 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1384 | 0.120 |
Why?
| | Magnetic Fields | 1 | 2013 | 23 | 0.120 |
Why?
| | Transposition of Great Vessels | 1 | 2014 | 28 | 0.120 |
Why?
| | Radiography | 2 | 2014 | 861 | 0.120 |
Why?
| | Protons | 1 | 2013 | 79 | 0.120 |
Why?
| | Electric Impedance | 1 | 2013 | 101 | 0.120 |
Why?
| | Cardiomyopathies | 1 | 2017 | 299 | 0.120 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 294 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2014 | 124 | 0.110 |
Why?
| | Drug Design | 1 | 2014 | 160 | 0.110 |
Why?
| | Cerebrovascular Circulation | 2 | 1991 | 204 | 0.110 |
Why?
| | Kidney | 2 | 2012 | 1353 | 0.110 |
Why?
| | Aortic Valve Insufficiency | 1 | 2012 | 42 | 0.110 |
Why?
| | Mitral Valve Insufficiency | 1 | 2012 | 62 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2012 | 95 | 0.110 |
Why?
| | Angiography | 3 | 2004 | 185 | 0.110 |
Why?
| | Pulmonary Artery | 1 | 2018 | 1063 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2012 | 118 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2012 | 162 | 0.100 |
Why?
| | Cerebral Infarction | 1 | 1991 | 45 | 0.100 |
Why?
| | Cardiac Valve Annuloplasty | 1 | 2010 | 1 | 0.100 |
Why?
| | Carbon Dioxide | 2 | 1991 | 230 | 0.100 |
Why?
| | Tricuspid Valve | 1 | 2010 | 23 | 0.090 |
Why?
| | Tricuspid Valve Insufficiency | 1 | 2010 | 18 | 0.090 |
Why?
| | Time Factors | 5 | 2017 | 6412 | 0.090 |
Why?
| | Pericardium | 1 | 2010 | 50 | 0.090 |
Why?
| | Equipment Design | 2 | 2009 | 519 | 0.090 |
Why?
| | Fourier Analysis | 3 | 2007 | 41 | 0.090 |
Why?
| | Case-Control Studies | 1 | 2017 | 3171 | 0.090 |
Why?
| | Bone Remodeling | 1 | 2010 | 64 | 0.090 |
Why?
| | Kidney Failure, Chronic | 1 | 2015 | 516 | 0.090 |
Why?
| | Guideline Adherence | 1 | 2014 | 523 | 0.090 |
Why?
| | Young Adult | 3 | 2016 | 10793 | 0.090 |
Why?
| | Ventricular Function, Left | 1 | 2012 | 468 | 0.090 |
Why?
| | Echocardiography | 1 | 2012 | 556 | 0.090 |
Why?
| | Hypertension, Renal | 1 | 2009 | 28 | 0.090 |
Why?
| | Spin Labels | 1 | 2009 | 50 | 0.080 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 139 | 0.080 |
Why?
| | Adolescent | 4 | 2016 | 18480 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 439 | 0.080 |
Why?
| | Scattering, Radiation | 1 | 2007 | 93 | 0.080 |
Why?
| | Models, Structural | 3 | 1991 | 38 | 0.080 |
Why?
| | Heart Valve Diseases | 1 | 2009 | 135 | 0.080 |
Why?
| | Pentetic Acid | 2 | 1997 | 12 | 0.070 |
Why?
| | Infusions, Intravenous | 2 | 1998 | 380 | 0.070 |
Why?
| | Brain | 4 | 1991 | 2490 | 0.070 |
Why?
| | Drug Combinations | 2 | 1997 | 291 | 0.070 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 55 | 0.070 |
Why?
| | Electrocardiography | 1 | 2009 | 556 | 0.070 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2006 | 81 | 0.070 |
Why?
| | Lung | 1 | 2017 | 3664 | 0.060 |
Why?
| | Arterial Occlusive Diseases | 1 | 2004 | 74 | 0.060 |
Why?
| | Vascular Diseases | 1 | 2007 | 241 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2007 | 345 | 0.060 |
Why?
| | Thrombosis | 1 | 2006 | 309 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2017 | 12978 | 0.050 |
Why?
| | Leg | 1 | 2004 | 234 | 0.050 |
Why?
| | Kidney Neoplasms | 1 | 2006 | 334 | 0.050 |
Why?
| | Animals | 7 | 2014 | 33381 | 0.050 |
Why?
| | Rats | 5 | 1991 | 5392 | 0.050 |
Why?
| | Hypertension, Renovascular | 2 | 2009 | 16 | 0.040 |
Why?
| | Neck | 1 | 1998 | 89 | 0.040 |
Why?
| | United States | 1 | 2014 | 12555 | 0.040 |
Why?
| | Head | 1 | 1998 | 89 | 0.040 |
Why?
| | Heart Failure | 1 | 2010 | 1969 | 0.040 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 394 | 0.040 |
Why?
| | Fetal Organ Maturity | 1 | 2017 | 26 | 0.040 |
Why?
| | Forms and Records Control | 1 | 2017 | 23 | 0.040 |
Why?
| | Technology Assessment, Biomedical | 1 | 2016 | 29 | 0.040 |
Why?
| | Ferric Compounds | 1 | 1997 | 39 | 0.040 |
Why?
| | Ultrasonography | 2 | 2014 | 716 | 0.040 |
Why?
| | Rheology | 2 | 2002 | 87 | 0.040 |
Why?
| | Safety | 1 | 1998 | 304 | 0.040 |
Why?
| | Treatment Outcome | 1 | 2010 | 9342 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4596 | 0.030 |
Why?
| | Efficiency, Organizational | 1 | 2017 | 126 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 554 | 0.030 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2015 | 64 | 0.030 |
Why?
| | Kidney Function Tests | 1 | 2015 | 164 | 0.030 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2017 | 508 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 243 | 0.030 |
Why?
| | Gestational Age | 1 | 2017 | 765 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 2013 | 58 | 0.030 |
Why?
| | Cerebrovascular Disorders | 1 | 2013 | 86 | 0.030 |
Why?
| | Contraindications | 1 | 2012 | 86 | 0.030 |
Why?
| | Fetus | 1 | 2017 | 690 | 0.030 |
Why?
| | Body Water | 1 | 1991 | 28 | 0.030 |
Why?
| | Acetone | 1 | 1991 | 10 | 0.020 |
Why?
| | Lasers | 1 | 1991 | 124 | 0.020 |
Why?
| | Edetic Acid | 1 | 1991 | 47 | 0.020 |
Why?
| | Gels | 1 | 1991 | 72 | 0.020 |
Why?
| | Dextrans | 1 | 1991 | 74 | 0.020 |
Why?
| | Corpus Striatum | 1 | 1991 | 127 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 1991 | 245 | 0.020 |
Why?
| | Child | 1 | 2010 | 19129 | 0.020 |
Why?
| | Muscles | 1 | 1991 | 333 | 0.020 |
Why?
| | Stroke Volume | 1 | 2012 | 513 | 0.020 |
Why?
| | Linear Models | 1 | 1991 | 827 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 1991 | 1094 | 0.020 |
Why?
| | Glomerular Filtration Rate | 1 | 2012 | 683 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 1991 | 416 | 0.020 |
Why?
| | Whole Body Imaging | 1 | 2007 | 25 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3057 | 0.020 |
Why?
| | Carotid Stenosis | 1 | 2007 | 75 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 968 | 0.020 |
Why?
| | Leiomyosarcoma | 1 | 2006 | 23 | 0.020 |
Why?
| | Clinical Protocols | 1 | 2006 | 238 | 0.020 |
Why?
| | Pregnancy | 1 | 2017 | 5691 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2674 | 0.020 |
Why?
| | Prognosis | 1 | 2012 | 3443 | 0.020 |
Why?
| | Reference Standards | 1 | 2004 | 176 | 0.020 |
Why?
| | Models, Biological | 1 | 1991 | 1715 | 0.010 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2002 | 19 | 0.010 |
Why?
| | Risk Factors | 1 | 2015 | 9000 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 2002 | 418 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2006 | 812 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 147 | 0.010 |
Why?
| | Reference Values | 1 | 1997 | 774 | 0.010 |
Why?
| | Death | 1 | 1991 | 105 | 0.010 |
Why?
| | Body Temperature | 1 | 1991 | 215 | 0.010 |
Why?
| | Cell Death | 1 | 1991 | 339 | 0.010 |
Why?
|
|
Maki's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|